Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes
Public ClinicalTrials.gov record NCT04982575. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Efficacy and Safety of Co-administration of Cagrilintide s.c. 2.4 mg and Semaglutide s.c. 2.4 mg Once Weekly in Subjects With Type 2 Diabetes
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study looks at how well a new medicine called cagrilintide works together with semaglutide on blood sugar levels in people with type 2 diabetes compared to cagrilintide alone or semaglutide alone. Before a new medicine can be prescribed to people it needs to be tested to see if it is safe and effective. Participants will either get cagrilintide and semaglutide together or cagrilintide and a dummy medicine or semaglutide and a dummy medicine. Which treatment participants get is decided by chance. A dummy medicine (placebo) looks like the study medicine but does not contain any active medicine. The dummy medicine is in the study to see if the study medicine works as expected. Participants will get 2 injections per week on the same day. Participants will take the study medicine with a pen. A pen is a medical tool with a needle used for injections under the skin. The study doctor or staff will show how. The study will last for about 39 weeks. Participants will have 12 visits at the clinic and 5 phone calls with the study doctor. At 6 of the clinic visits participants must not eat and drink for 8 hours before the visit (water is allowed). Women who can become pregnant cannot take part in this study. Only women that are surgically sterilised or post-menopausal are allowed to participate in this study Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period
Study identification
- NCT ID
- NCT04982575
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 92 participants
Conditions and interventions
Conditions
Interventions
- Semaglutide 2.4 mg Drug
- Cagrilintide 2.4 mg Drug
- Placebo (semaglutide) Drug
- Placebo (cagrilintide) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 1, 2021
- Primary completion
- Jul 6, 2022
- Completion
- Jul 6, 2022
- Last update posted
- Dec 22, 2025
2021 – 2022
United States locations
- U.S. sites
- 23
- U.S. states
- 14
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Uni of Alabama at Birmingham | Birmingham | Alabama | 35233 | — |
| Valley Research | Fresno | California | 93720 | — |
| Pacific Clinical Studies | Los Alamitos | California | 90720 | — |
| Velocity Clin Res Los Angeles | Los Angeles | California | 90017 | — |
| Encompass Clinical Research_Spring Valley | Spring Valley | California | 91978 | — |
| New West Physicians,Inc. | Golden | Colorado | 80401 | — |
| FPA Clinical Research | Kissimmee | Florida | 34741 | — |
| Florida Inst For Clin Res | Orlando | Florida | 32825 | — |
| Clinical Trial Res Assoc,Inc | Plantation | Florida | 33324 | — |
| Ellipsis Group | Alpharetta | Georgia | 30022 | — |
| East West Med Res Inst | Honolulu | Hawaii | 96814 | — |
| Macoupin Research Group | Gillespie | Illinois | 62033 | — |
| MD Medical Research | Oxon Hill | Maryland | 20745 | — |
| PharmQuest Life Sciences LLC | Greensboro | North Carolina | 27408 | — |
| Accellacare | Wilmington | North Carolina | 28401 | — |
| Lillestol Research LLC | Fargo | North Dakota | 58104 | — |
| Plains Clinical Research Center, LLC_Fargo | Fargo | North Dakota | 58104 | — |
| Holston Medical Group | Kingsport | Tennessee | 37660 | — |
| Velocity Clinical Res-Dallas | Dallas | Texas | 75230 | — |
| PlanIt Research, PLLC | Houston | Texas | 77079 | — |
| DCOL Ctr for Clin Res | Longview | Texas | 75605 | — |
| Selma Medical Associates | Winchester | Virginia | 22601-3834 | — |
| Capital Clin Res Ctr,LLC | Olympia | Washington | 98502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04982575, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 22, 2025 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04982575 live on ClinicalTrials.gov.